Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

Xu, Dan-yan; Zhao, Shui-Ping; Huang, Qiu-xia; Du, Wei; Liu, Yu-hua; Liu, Ling; Xie, Xiao-mei

doi:10.1016/j.diabres.2009.12.010

« Previous Next »Diabetes Research and Clinical Practice
Volume 88, Issue 1 , Pages 71-75, April 2010

Effects of Glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus

Dan-yan Xu
- Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China
- Corresponding author at: Department of Cardiology, Internal Medicine, Second Xiangya Hospital, 139 Middle Renming Road, Changsha, Hunan 410011, PR China. Tel.: +86 731 5292100; fax: +86 731 4895989.
Shui-Ping Zhao
- Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China
Qiu-xia Huang
- Department of Endocrinology, The People's Hospital of Dongguan City, Dongguan, Guangdong, 523018, PR China
Wei Du
- Department of Endocrinology, The People's Hospital of Dongguan City, Dongguan, Guangdong, 523018, PR China
Yu-hua Liu
- Department of Endocrinology, The People's Hospital of Dongguan City, Dongguan, Guangdong, 523018, PR China
Ling Liu
- Department of Cardiology, Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, PR China
Xiao-mei Xie
- Department of Geriatrics, Second Xiangya Hospital, Central South University, Changsha, 410011, PR China

Received 20 September 2007; received in revised form 10 July 2009; accepted 8 December 2009. published online 04 January 2010.

Abstract

Background

To investigate the effects of Glimepiride on blood glucose in patients with newly diagnosed type 2 diabetes mellitus (T2DM) in connection with plasma lipoproteins and plasminogen activity.

Methods

A total of 565 T2DM patients were received Glimepiride (n=333) or Glibenclamide (n=232) for 12 weeks. We observed the level of blood glucose (BG), glycated hemoglobin (HbA1C), the insulin resistance (IR) state, plasma lipoproteins, tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type I (PAI-1) before and after a 12 weeks of treatment.

Results

After 12 weeks with Glimepiride treatment, significant reductions were observed in fasting blood glucose (FBG) and 2-h postprandial BG(PBG), HbA1C (from 8.60±3.10 to 7.10±1.60%) and HOMA-IR (from 4.11±0.85 to 2.42±0.91%). The level of total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) were significantly decreased, whereas that of high-density lipoprotein (HDL) was increased markedly with statistical significance. In addition, there was an obvious improvement in t-PA activity (from 0.225±0.11 to 0.457±0.177IU/ml); whereas the PAI-1 activity was decreased significantly (from 0.898±0.168 to 0.533±0.215AU/ml). No significant changes were observed in plasma lipoprotein profiles and plasminogen activity in Glibenclamide receiving group.

Conclusions

Glimepiride can rapidly and stably improve glycemic control and lipoprotein metabolism, significantly alleviate insulin resistance and enhance fibrinolytic activity.

Keywords: Type 2 diabetes mellitus (T2DM), Glimepiride, Blood glucose (BG), Plasma lipoprotein, Tissue plasminogen activator (t-PA), Plasminogen activator inhibitor type I (PAI-1)